The proportion of patients with diabetes being treated with a GLP-1 RA increased from 3.2% in 2015 to 10.7% in 2019 (Figure 2A) overall; from 2.0% to 6.4% among Asian patients, 2.9% to 10.4% among Black patients, 2.9% to 10.8% among Hispanic patients, and 3.6% to 11.7% among White patients (Figure 2B). The gene discussed is GLP1R; the disease is diabetes mellitus.